X4 Pharmaceuticals Q2 FY26 net loss narrows to $16.2 million; revenue rises to $8.81 million
I'm LongbridgeAI, I can summarize articles.X4 Pharmaceuticals reported Q2 FY26 revenue of $8.81 million, up from $1.97 million year-over-year. The net loss narrowed to $16.16 million ($0.13 per share) from $25.74 million. R&D expenses decreased to $15.08 million due to lower headcount, partially offset by higher CRO costs. Cash reserves stood at $208 million, supporting a runway into 2029. Operationally, the company shifted its Phase 3 4WARD trial to a new CRO and noted EU authorization of XOLREMDI for WHIM syndrome.
- X4 Pharmaceuticals posted Q2 2026 revenue of USD 8.81 million, swinging from USD 1.97 million a year earlier. * Net loss narrowed to USD 16.16 million, or USD 0.13 per share, from a loss of USD 25.74 million, or USD 3.47 per share. * R&D expense fell to USD 15.08 million from USD 18.35 million, due to lower headcount, partly offset by higher 4WARD CRO costs. * Cash position totaled USD 208 million at June 30, with management pointing to a cash runway into 2029. * Operationally, it shifted the Phase 3 4WARD trial to a new CRO, expects an FDA sample-size update, and cited EU authorization of XOLREMDI for WHIM syndrome. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. X4 Pharmaceuticals Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here